FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma

Olga V. Danilova, Larry J. Dumont, Norman B. Levy, Frederick Lansigan, William B. Kinlaw, Alexey Danilov, Prabhjot Kaur

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Diffuse large B-cell lymphoma is the most common lymphoid malignancy, as it accounts for approximately one third of all patient cases of non-Hodgkin's lymphoma. Patients with diffuse large B-cell lymphoma have markedly different treatment outcomes, suggesting a need for reliable prognostic factors and novel therapeutic approaches. De novo fatty acid synthesis is an important metabolic driver of tumor in multiple malignancies. In this retrospective study, we analyzed expression of fatty acid synthase (a key enzyme in de novo fatty acid synthesis), Spot 14 (thyroid hormone responsive Spot 14, a nuclear protein that promotes expression of genes involved in fatty acid synthesis), and CD36 (the cell surface channel for exogenous fatty acid uptake) in patients with diffuse large B-cell lymphoma and their clinical significance. We observed that overexpression of fatty acid synthase is negatively associated with overall survival (p = 0. 001) and progression-free period (p = 0. 004) in patients with diffuse large B-cell lymphoma. Multivariate analysis showed that fatty acid synthase overexpression is an independent prognostic marker of aggressive clinical course. For the first time, we report CD36 as an independent protective factor in patients treated with rituximab. Thus, fatty acid synthase and CD36 expression may serve as prognostic markers to predict response to treatment and survival in diffuse large B-cell lymphoma patients. Fatty acid synthase may also be a potential therapeutic target in lymphoid malignancies.

Original languageEnglish (US)
Pages (from-to)11-18
Number of pages8
JournalJournal of Hematopathology
Volume6
Issue number1
DOIs
StatePublished - 2013
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Fatty Acid Synthases
Survival
Fatty Acids
Neoplasms
Nuclear Proteins
Thyroid Hormones
Non-Hodgkin's Lymphoma
Rituximab
Therapeutics
Multivariate Analysis
Retrospective Studies
Biomarkers
Gene Expression
Enzymes

Keywords

  • CD36
  • Diffuse large B-cell lymphoma
  • Fatty acid synthase
  • Lipogenesis
  • S14
  • Survival

ASJC Scopus subject areas

  • Hematology
  • Pathology and Forensic Medicine
  • Histology

Cite this

Danilova, O. V., Dumont, L. J., Levy, N. B., Lansigan, F., Kinlaw, W. B., Danilov, A., & Kaur, P. (2013). FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma. Journal of Hematopathology, 6(1), 11-18. https://doi.org/10.1007/s12308-012-0166-4

FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma. / Danilova, Olga V.; Dumont, Larry J.; Levy, Norman B.; Lansigan, Frederick; Kinlaw, William B.; Danilov, Alexey; Kaur, Prabhjot.

In: Journal of Hematopathology, Vol. 6, No. 1, 2013, p. 11-18.

Research output: Contribution to journalArticle

Danilova, OV, Dumont, LJ, Levy, NB, Lansigan, F, Kinlaw, WB, Danilov, A & Kaur, P 2013, 'FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma', Journal of Hematopathology, vol. 6, no. 1, pp. 11-18. https://doi.org/10.1007/s12308-012-0166-4
Danilova, Olga V. ; Dumont, Larry J. ; Levy, Norman B. ; Lansigan, Frederick ; Kinlaw, William B. ; Danilov, Alexey ; Kaur, Prabhjot. / FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma. In: Journal of Hematopathology. 2013 ; Vol. 6, No. 1. pp. 11-18.
@article{fa6c752a2b104c868c70df988c40c1a1,
title = "FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma",
abstract = "Diffuse large B-cell lymphoma is the most common lymphoid malignancy, as it accounts for approximately one third of all patient cases of non-Hodgkin's lymphoma. Patients with diffuse large B-cell lymphoma have markedly different treatment outcomes, suggesting a need for reliable prognostic factors and novel therapeutic approaches. De novo fatty acid synthesis is an important metabolic driver of tumor in multiple malignancies. In this retrospective study, we analyzed expression of fatty acid synthase (a key enzyme in de novo fatty acid synthesis), Spot 14 (thyroid hormone responsive Spot 14, a nuclear protein that promotes expression of genes involved in fatty acid synthesis), and CD36 (the cell surface channel for exogenous fatty acid uptake) in patients with diffuse large B-cell lymphoma and their clinical significance. We observed that overexpression of fatty acid synthase is negatively associated with overall survival (p = 0. 001) and progression-free period (p = 0. 004) in patients with diffuse large B-cell lymphoma. Multivariate analysis showed that fatty acid synthase overexpression is an independent prognostic marker of aggressive clinical course. For the first time, we report CD36 as an independent protective factor in patients treated with rituximab. Thus, fatty acid synthase and CD36 expression may serve as prognostic markers to predict response to treatment and survival in diffuse large B-cell lymphoma patients. Fatty acid synthase may also be a potential therapeutic target in lymphoid malignancies.",
keywords = "CD36, Diffuse large B-cell lymphoma, Fatty acid synthase, Lipogenesis, S14, Survival",
author = "Danilova, {Olga V.} and Dumont, {Larry J.} and Levy, {Norman B.} and Frederick Lansigan and Kinlaw, {William B.} and Alexey Danilov and Prabhjot Kaur",
year = "2013",
doi = "10.1007/s12308-012-0166-4",
language = "English (US)",
volume = "6",
pages = "11--18",
journal = "Journal of Hematopathology",
issn = "1865-5785",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma

AU - Danilova, Olga V.

AU - Dumont, Larry J.

AU - Levy, Norman B.

AU - Lansigan, Frederick

AU - Kinlaw, William B.

AU - Danilov, Alexey

AU - Kaur, Prabhjot

PY - 2013

Y1 - 2013

N2 - Diffuse large B-cell lymphoma is the most common lymphoid malignancy, as it accounts for approximately one third of all patient cases of non-Hodgkin's lymphoma. Patients with diffuse large B-cell lymphoma have markedly different treatment outcomes, suggesting a need for reliable prognostic factors and novel therapeutic approaches. De novo fatty acid synthesis is an important metabolic driver of tumor in multiple malignancies. In this retrospective study, we analyzed expression of fatty acid synthase (a key enzyme in de novo fatty acid synthesis), Spot 14 (thyroid hormone responsive Spot 14, a nuclear protein that promotes expression of genes involved in fatty acid synthesis), and CD36 (the cell surface channel for exogenous fatty acid uptake) in patients with diffuse large B-cell lymphoma and their clinical significance. We observed that overexpression of fatty acid synthase is negatively associated with overall survival (p = 0. 001) and progression-free period (p = 0. 004) in patients with diffuse large B-cell lymphoma. Multivariate analysis showed that fatty acid synthase overexpression is an independent prognostic marker of aggressive clinical course. For the first time, we report CD36 as an independent protective factor in patients treated with rituximab. Thus, fatty acid synthase and CD36 expression may serve as prognostic markers to predict response to treatment and survival in diffuse large B-cell lymphoma patients. Fatty acid synthase may also be a potential therapeutic target in lymphoid malignancies.

AB - Diffuse large B-cell lymphoma is the most common lymphoid malignancy, as it accounts for approximately one third of all patient cases of non-Hodgkin's lymphoma. Patients with diffuse large B-cell lymphoma have markedly different treatment outcomes, suggesting a need for reliable prognostic factors and novel therapeutic approaches. De novo fatty acid synthesis is an important metabolic driver of tumor in multiple malignancies. In this retrospective study, we analyzed expression of fatty acid synthase (a key enzyme in de novo fatty acid synthesis), Spot 14 (thyroid hormone responsive Spot 14, a nuclear protein that promotes expression of genes involved in fatty acid synthesis), and CD36 (the cell surface channel for exogenous fatty acid uptake) in patients with diffuse large B-cell lymphoma and their clinical significance. We observed that overexpression of fatty acid synthase is negatively associated with overall survival (p = 0. 001) and progression-free period (p = 0. 004) in patients with diffuse large B-cell lymphoma. Multivariate analysis showed that fatty acid synthase overexpression is an independent prognostic marker of aggressive clinical course. For the first time, we report CD36 as an independent protective factor in patients treated with rituximab. Thus, fatty acid synthase and CD36 expression may serve as prognostic markers to predict response to treatment and survival in diffuse large B-cell lymphoma patients. Fatty acid synthase may also be a potential therapeutic target in lymphoid malignancies.

KW - CD36

KW - Diffuse large B-cell lymphoma

KW - Fatty acid synthase

KW - Lipogenesis

KW - S14

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84889236808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889236808&partnerID=8YFLogxK

U2 - 10.1007/s12308-012-0166-4

DO - 10.1007/s12308-012-0166-4

M3 - Article

VL - 6

SP - 11

EP - 18

JO - Journal of Hematopathology

JF - Journal of Hematopathology

SN - 1865-5785

IS - 1

ER -